ZA200701137B - Triazolophthalazines - Google Patents

Triazolophthalazines

Info

Publication number
ZA200701137B
ZA200701137B ZA200701137A ZA200701137A ZA200701137B ZA 200701137 B ZA200701137 B ZA 200701137B ZA 200701137 A ZA200701137 A ZA 200701137A ZA 200701137 A ZA200701137 A ZA 200701137A ZA 200701137 B ZA200701137 B ZA 200701137B
Authority
ZA
South Africa
Prior art keywords
triazolophthalazines
meanings
compounds
formula
given
Prior art date
Application number
ZA200701137A
Other languages
English (en)
Inventor
Schmidt Beate
Weinbrenner Steffen
Flockerzi Dieter
Kuelzer Raimund
Tenor Hermann
Kley Hans-Peter
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of ZA200701137B publication Critical patent/ZA200701137B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
ZA200701137A 2004-09-02 2007-02-08 Triazolophthalazines ZA200701137B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04104221 2004-09-02

Publications (1)

Publication Number Publication Date
ZA200701137B true ZA200701137B (en) 2008-11-26

Family

ID=34929521

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200701137A ZA200701137B (en) 2004-09-02 2007-02-08 Triazolophthalazines

Country Status (18)

Country Link
US (2) US7851472B2 (ja)
EP (1) EP1791543B1 (ja)
JP (1) JP5140427B2 (ja)
KR (1) KR101368093B1 (ja)
CN (1) CN101133057B (ja)
AT (1) ATE471324T1 (ja)
AU (1) AU2005279221C9 (ja)
BR (1) BRPI0514586A (ja)
CA (1) CA2578368C (ja)
DE (1) DE602005021894D1 (ja)
EA (1) EA014324B1 (ja)
ES (1) ES2347337T3 (ja)
HK (1) HK1115590A1 (ja)
IL (1) IL181271A (ja)
NO (1) NO20071127L (ja)
NZ (1) NZ553160A (ja)
WO (1) WO2006024640A2 (ja)
ZA (1) ZA200701137B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5240899B2 (ja) * 2005-01-05 2013-07-17 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
US7671050B2 (en) 2005-01-05 2010-03-02 Nycomed Gmbh Triazolophthalazines
CN102791715B (zh) 2009-12-31 2016-04-27 卡洛斯三世国家癌症研究中心基金会 用作激酶抑制剂的三环化合物
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
HRP20212035T1 (hr) 2014-04-23 2022-04-01 Dart Neuroscience Llc Pripravci koji sadrže supstituirane [1,2,4]triazolo[1,5-a]pirimidin-7-il spojeve kao inhibitore pde2
EP3215508A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
WO2016090380A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
EP3285581B1 (en) 2015-03-26 2021-08-11 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
JP2021504466A (ja) * 2017-11-23 2021-02-15 オスロ ウニヴェルシティ ホスピタル ホーエフ 頻脈の治療

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI81350C (fi) 1982-01-18 1990-10-10 Lepetit Spa Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat.
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
AU695377B2 (en) * 1994-09-16 1998-08-13 Takeda Chemical Industries Ltd. Triazolopyridazines process and intermediates for their preparation and their use as medicaments
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
DE69720732T2 (de) 1996-07-25 2004-01-29 Merck Sharp & Dohme Substituierte Triazolo-Pyridazin-Derivate als Liganden von GABA-Rezeptoren
WO1998050385A1 (en) 1997-05-08 1998-11-12 Merck Sharp & Dohme Limited SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
GB9715977D0 (en) 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
GB0028583D0 (en) 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
WO2002083140A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
JP5240899B2 (ja) * 2005-01-05 2013-07-17 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
US7671050B2 (en) * 2005-01-05 2010-03-02 Nycomed Gmbh Triazolophthalazines

Also Published As

Publication number Publication date
WO2006024640A2 (en) 2006-03-09
WO2006024640A3 (en) 2007-06-07
ATE471324T1 (de) 2010-07-15
IL181271A (en) 2013-11-28
DE602005021894D1 (de) 2010-07-29
EA200700537A1 (ru) 2007-10-26
IL181271A0 (en) 2007-07-04
US20100286140A1 (en) 2010-11-11
EA014324B1 (ru) 2010-10-29
US7851472B2 (en) 2010-12-14
HK1115590A1 (en) 2008-12-05
CA2578368A1 (en) 2006-03-09
EP1791543B1 (en) 2010-06-16
AU2005279221C9 (en) 2012-08-23
CN101133057A (zh) 2008-02-27
NZ553160A (en) 2010-08-27
JP2008511586A (ja) 2008-04-17
CA2578368C (en) 2013-07-02
AU2005279221A1 (en) 2006-03-09
AU2005279221B2 (en) 2011-10-13
EP1791543A2 (en) 2007-06-06
AU2005279221C1 (en) 2012-05-24
KR20070047834A (ko) 2007-05-07
CN101133057B (zh) 2011-03-09
JP5140427B2 (ja) 2013-02-06
US20090005372A1 (en) 2009-01-01
NO20071127L (no) 2007-02-28
ES2347337T3 (es) 2010-10-28
KR101368093B1 (ko) 2014-03-14
BRPI0514586A (pt) 2008-06-17

Similar Documents

Publication Publication Date Title
HK1115590A1 (en) Triazolophthalazines
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
TW200640924A (en) VEGF-R2 inhibitors and methods
SI1761520T1 (sl) Inhibitorji kinaze
SG161318A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
MX2007005932A (es) 1-alquinil-2-ariloxialquilamidas y su uso como fungicidas.
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
EA200701707A1 (ru) Пиразолопиримидины
UA85505C2 (en) Kinase inhibitors
MX2008001538A (es) Aril piridinas y metodos para su uso.
WO2004110990A3 (en) Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
MY154498A (en) Pyrazolone derivatives as pde4 inhibitors
MX2008001541A (es) Metodos para la preparacion de inhibidores de polimerasa del vhc.
EA200702584A1 (ru) Спиробензимидазолы как ингибиторы секреции соляной кислоты
ATE508130T1 (de) 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren
GB0226550D0 (en) Organic compounds
MD2731B2 (ja)